Skip to main content
Livermore
Livermore
ZHEN

Kyntra Bio, Inc.

KYNB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000921299

No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.

Holders of 5% or more of KYNB

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Kyntra Bio, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of KYNB
HolderLatest formStakeChangeFirst filedLatest filingFiling
Armistice Capital, LLC13G/A9.35%378.0K shares+1.04 ppfrom 8.31%Feb 14, 20254 filingsNov 14, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

6 Schedule 13D and 13G filings on Kyntra Bio, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on KYNB
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 14, 20256:41 PM ETArmistice Capital, LLCand 1 other13G/A9.35%378.0K shares+1.04 ppfrom 8.31%Sep 30, 2025SEC
Aug 15, 202512:24 PM ETArmistice Capital, LLCand 1 other13G/A8.31%336.0K shares−0.11 ppfrom 8.42%Jun 30, 2025SEC
Jul 29, 202510:34 AM ETVanguard Group Inc13G/A4.40%178.0K shares–Below 5%Jun 30, 2025SEC
May 15, 20253:27 PM ETArmistice Capital, LLCand 1 other13G/A8.42%8.50M shares+1.67 ppfrom 6.75%Mar 31, 2025SEC
Feb 14, 20255:49 PM ETArmistice Capital, LLCand 1 other13G/A6.75%6.80M shares–Dec 31, 2024SEC
Feb 13, 20256:24 PM ETPrimecap Management Co13G/A4.58%4.62M shares–Below 5%Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Kyntra Bio, Inc. shares.

No Form 144 notices for Kyntra Bio, Inc. are on file.